"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 3 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 3 | 4 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 3 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 1 | 2 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
Gusovsky AV, Lin CC, Kerber K, Reynolds EL, Callaghan BC, Burke JF. Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications. Neurology. 2024 Nov 26; 103(10):e210029.
-
Valikodath NG, Rathinavelu J, Deaner JD, Buckley M, Grewal DS. Comparison of Reference and Biosimilar Medications for Pediatric Noninfectious Uveitis. Int Ophthalmol Clin. 2024 Oct 01; 64(4):69-73.
-
Neumann S, Alverson B. Nirsevimab: The Hidden Costs. Hosp Pediatr. 2024 May 09; 14(6).
-
Wong ND, Bang M, Block RC, Peterson ALH, Karalis DG. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists). Am J Cardiol. 2021 08 01; 152:57-62.
-
Barbarite E, Occhiogrosso J, McCarty JC, Lee LN, Hadlock TA, Shaye DA, Gadkaree SK. Opioid Prescribing Patterns Among Facial Plastic and Reconstructive Surgeons in the Medicare Population. Facial Plast Surg Aesthet Med. 2021 12; 23(6):401-404.
-
Bluher AE, Moody-Antonio S. Rising Costs of Otic Drops: Review of a National Database. Laryngoscope. 2021 04; 131(4):E1069-E1075.
-
Goudra B, Singh PM, Lichtenstein GR. Medical, Political, and Economic Considerations for the Use of MAC for Endoscopic Sedation: Big Price, Little Justification? Dig Dis Sci. 2020 09; 65(9):2466-2472.
-
Wilson CW, Hock LE, Oetting T, Kennedy S, Terveen D. Pupil expansion device use and operative outcomes with topical dilation vs intracameral epinephrine in resident-performed cataract surgery. J Cataract Refract Surg. 2020 04; 46(4):562-566.
-
Magnuson EA, Chinnakondepalli K, Vilain K, Kearon C, Julian JA, Kahn SR, Goldhaber SZ, Jaff MR, Kindzelski AL, Herman K, Brady PS, Sharma K, Black CM, Vedantham S, Cohen DJ. Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial. Circ Cardiovasc Qual Outcomes. 2019 10; 12(10):e005659.
-
Epstein D, Esp?n J. Evaluation of new medicines in Spain and comparison with other European countries. Gac Sanit. 2020 Mar - Apr; 34(2):133-140.